Overview of Promixin

Quick Facts

Property	Description
Active ingredient	Colistimethate Sodium (CMS)
Form	Lyophilised Powder for Solution
Pharmacological class	Polypeptide Antibiotic (Polymyxin Group)
Common Use	Treating severe infections caused by resistant bacteria
Origin	Synthetic Prodrug

What Type of Drug Is Promixin? (Identity and Classification)

Promixin is a potent, prescription-only anti-infective agent whose active substance is Colistimethate Sodium (CMS). The drug is classified as a polypeptide antibiotic belonging to the Polymyxin group. This medication holds a critical designation in clinical settings, often reserved as a last-resort antibiotic due to its specific activity against highly resistant pathogens. CMS is primarily used to treat serious infections caused by Gram-negative bacteria resistant to other antibiotics. This means that for patients facing hard-to-treat infections, Promixin provides a necessary alternative when most standard treatments have failed. It is clinically recognized for its utility in managing infections related to conditions like Cystic Fibrosis, particularly when chronic pulmonary Pseudomonas aeruginosa infection is present.

Composition and Administration Form (Substance and Vehicle)

The core active ingredient is Colistimethate Sodium (CMS), a synthetic prodrug that must undergo transformation within the body to release the active compound, Colistin. CMS is formulated as a sterile, lyophilised powder that requires careful reconstitution with an aqueous solvent, such as sterile water or saline solution, immediately before administration. This preparation method enables administration either via intravenous infusion for systemic infections or for inhalation (nebulised) to address localized infections in the respiratory tract. The final product is supplied in vials designed for single use, ensuring product stability and precise dosing as a single-ingredient product.

General Therapeutic Purpose and Benefit

The general therapeutic purpose of Promixin is to control or eliminate challenging Gram-negative bacteria through a unique bactericidal action. The active component, Colistin, works by physically disrupting the integrity of the bacterial cell's outer membrane, which effectively causes the organism to die. This distinct, membrane-disrupting mechanism is the source of its primary benefit: providing a powerful treatment option against pathogens that have developed broad resistance to most other commonly used antibiotic classes. Its efficacy against these resilient organisms offers a critical defense line for patients where therapeutic failure due to bacterial resistance is a major clinical risk.

Regulatory References

Promixin (Colistimethate Sodium) EPAR

What side effects are possible with Promixin?

Possible Side Effects and Safety Information

The safety profile of Colistimethate Sodium (Promixin) is primarily structured by the risk of systemic toxicity, specifically affecting the kidneys and nervous system, and by adverse effects that differ based on the administration route.

System-Organ Class Adverse Reactions

The most critical documented adverse effects involve Renal and Urinary Disorders, referred to as nephrotoxicity, which involves the impairment of renal function and can lead to acute renal insufficiency. Effects related to Nervous System Disorders (neurotoxicity) are also frequently observed with systemic use, manifesting as paresthesia (tingling or numbness of the extremities or mouth), dizziness, vertigo, and, less commonly, confusion or seizures. When administered via nebulisation, Respiratory, Thoracic, and Mediastinal Disorders are the most common concern, including cough, bronchospasm, and chest tightness.

Frequency and Seriousness Classification

Respiratory reactions like cough and bronchospasm are classified in regulatory documents as Very Common following nebulisation. Systemic effects such as paresthesia and renal impairment are typically classified as Common. Officially documented Serious Adverse Reactions include Apnea (respiratory arrest), acute renal insufficiency, and seizures.

Population-Specific and Dose-Related Safety Notes

The risk of both nephrotoxicity and neurotoxicity is explicitly documented as dose-dependent; higher plasma concentrations correlate with greater risk. Regulatory labeling highlights special safety considerations for certain populations. Patients with pre-existing renal impairment face an increased risk of toxicity. Similarly, use in individuals with conditions such as Myasthenia Gravis requires particular caution due to a heightened risk of muscle weakness and respiratory paralysis. Furthermore, the drug is known to cross the placental barrier, requiring specific safety assessment during pregnancy.

Overdose and Emergency Response

Overdose Scope

The official regulatory profile for Promixin (Colistimethate Sodium) focuses on two critical, dose-dependent toxicities that define the required emergency response.

Feature	Official Regulatory Statements
Documented overdose presentations	Neurotoxicity signs, including paresthesia (tingling or numbness), dizziness, vertigo, slurred speech, confusion, mental disturbance, and flushing.
Physiological systems affected	Renal system (leading to acute renal insufficiency/nephrotoxicity) and Neuromuscular system (leading to muscle weakness and apnea).
Emergency-response statements	Medication must be discontinued immediately if signs of impaired renal function occur. If respiratory paralysis occurs, respiration should be assisted as required.
When immediate medical help is required	Urgent medical attention is required for life-threatening outcomes such as apnea (respiratory arrest) or severe muscle weakness. Patients should contact a doctor straight away if they suspect an overdose.
Population-specific overdose notes	The risk of apnea and neuromuscular blockade is increased in patients with impaired renal function. Caution is specifically advised for infants under 1 year of age due to immature renal function.

Overdose Classifications (High-Level)

Classification Aspect	Official Regulatory Statements
Severity classification	Overdose can lead to severe and life-threatening outcomes, specifically acute renal insufficiency and apnea.
Overdose-context constraints	No specific antidote is known; management is limited to early cessation of the medication and appropriate symptomatic and supportive treatment.

Connection to the Overall Overdose Profile

Regulatory documents define the Promixin overdose profile by linking high serum concentrations to the two toxicological domains: nephrotoxicity and neurotoxicity. The guidance mandates immediate medical attention for severe manifestations like respiratory paralysis or evidence of acute renal failure. The official profile constrains response to supportive management and immediate drug discontinuation, as no specific antidote is known.

Therapeutic Uses of Promixin

What Promixin Treats: Main Uses and Benefits

Promixin is used for managing specific, serious infections, providing a relevant therapeutic option when other standard antibiotics may be ineffective due to resistance. This medication is applied across domains where additional symptomatic support is needed.

Management of Chronic Lung Infection in Cystic Fibrosis

Promixin is commonly used for managing chronic pulmonary colonization in patients with Cystic Fibrosis (CF) who experience persistent presence of Pseudomonas aeruginosa. This application is relevant for conditions involving episodic or fluctuating manifestations. This use may assist with managing the bacterial presence and contributes to easing the impact of pulmonary exacerbations, which are periods of symptoms that become more disruptive during flare-ups. This supportive role helps in addressing the potential for functional stability to become affected by chronic infection.

Last-Resort Treatment for Multidrug-Resistant Organisms

This medication is considered relevant as an antibiotic for serious infections that may be used when other treatment options are limited. It is applied in clinical settings that involve acute or unstable symptom patterns, such as in critical care for serious infections like ventilator-associated pneumonia. A benefit is that it provides support that helps ease the overall symptom burden in such situations. This assists with maintaining functional stability during difficult episodes and helps patients cope more steadily with symptoms related to systemic imbalance.

Quick Fact: Contextual Use in Chronic Pulmonary Symptoms

Category	Typical Use Context	Primary Symptom Axis Addressed
Therapeutic Domain	Long-term suppressive management	Symptoms related to chronic bacterial colonization
Conditions	Cystic Fibrosis (CF)	Symptoms that become more disruptive during flare-ups
Patient Benefit	Assists with addressing functional stability in the lungs	Helps address functional strain on the respiratory system

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Promixin — Official Regulatory Information

The eligibility profile for Promixin (Colistimethate Sodium) is defined by mandatory exclusions and restrictions set by regulatory authorities, such as the FDA and EMA.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults, adolescents, and children (systemic use for serious infections); Cystic Fibrosis (CF) patients for chronic pulmonary Pseudomonas aeruginosa (inhaled use) (Source 1.3, 3.2).
Populations for whom use is not recommended	Breastfeeding women (due to excretion in milk); pregnant women unless the potential benefit justifies the potential risk to the fetus, as the drug crosses the placental barrier (Source 1.1, 2.4).
Populations for whom use is contraindicated	Patients with a known history of hypersensitivity or allergy to colistimethate sodium, colistin, or other polymyxins (Source 1.4, 1.7).
Condition-specific eligibility rules	Impaired renal function requires the greatest caution and mandatory dosage modification proportional to the degree of impairment (Source 1.3, 2.2). Patients with Myasthenia Gravis require the greatest caution, and this condition is an absolute contraindication in some regulatory documents (Source 1.3, 1.7).
Age-related eligibility rules	Children under 6 years (inhaled formulation for CF) often have not had safety and efficacy established (Source 2.7). Infants under 1 year and older people require caution due to potential immaturity or age-related decline in renal function (Source 1.1, 3.2).

Resulting Eligibility Structure

The regulatory documents define Promixin's eligibility by absolute exclusion based on hypersensitivity and critical physiological restrictions, primarily focused on renal function. Use in patients with kidney impairment is conditional, requiring mandatory dose reduction as explicitly stated in the official labeling. Use during pregnancy, lactation, and in specific pediatric age sub-groups is categorized as restricted due to insufficient safety data or physiological caution (Source 1.3, 2.4).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Promixin (Colistimethate Sodium) is defined by its potential for additive organ toxicity and neuromuscular system potentiation.

Category	Official Regulatory Classification
Avoided Combinations	Co-administration with Sodium Cephalothin or other nephrotoxic medicinal products (including Aminoglycoside antibiotics) must be avoided due to the documented risk of summative kidney damage. Use with other neurotoxic medicinal products is also restricted.
Pharmacodynamic Potentiation	Promixin potentiates the neuromuscular blocking effects of non-depolarising muscle relaxants (such as Tubocurarine) and certain other antibiotics (e.g., Polymyxins, Aminoglycosides). These combinations should be used only with the greatest caution.
Pharmacokinetic Considerations	Regulatory information confirms that Colistimethate Sodium did not induce the activity of major CYP P450 enzymes in laboratory studies. However, the potential for interaction exists with medicinal products that are substrates for renal carrier mechanisms.
Population-Specific Cautions	Co-treatment with macrolide or fluoroquinolone antibiotics in patients with Myasthenia Gravis requires the greatest caution. The possibility of apnea and neuromuscular blockade is significantly increased in patients with impaired renal function.

Official interaction statements establish procedural constraints, such as the requirement to avoid mixing Promixin with other infusions, injections, or nebuliser solutions. The overall interaction structure is based on regulatory requirements to formally mitigate the risks associated with this drug's profile.

Mechanism of Action

Promixin, containing the prodrug colistimethate sodium (CMS), is a cationic polypeptide which undergoes hydrolysis in vivo to yield the active compound, colistin (polymyxin E). When administered via inhalation, the active colistin moiety achieves high local concentration within the pulmonary epithelial lining fluid. Its biological target is the outer membrane of susceptible Gram-negative bacteria, specifically interacting with the anionic lipopolysaccharide (LPS) molecules. Colistin, being polycationic, interacts electrostatically with the negatively charged phosphate groups of LPS, displacing the stabilizing divalent cations, Mg^2+ and Ca^2+. This detergent-like mechanism of action leads to a significant disruption and destabilization of the bacterial outer membrane integrity. The perturbation results in increased permeability of the cell envelope and subsequent leakage of essential intracellular components, ultimately inducing rapid bacterial cell death. Additionally, there is evidence that the drug may enter the bacterial cell and precipitate cytoplasmic components.

Dosage and Administration Information

Promixin (Colistimethate Sodium) is administered via two distinct routes: intravenous (IV) infusion for systemic infections and nebulised inhalation for localized lung treatment, such as in Cystic Fibrosis. The medication is a lyophilised powder that requires immediate reconstitution with a sterile diluent before use.

For systemic treatment, dosing is standardized, often requiring a loading dose (e.g., 9 Million International Units, MIU) followed by a maintenance dose administered in divided daily schedules. The final intravenous solution must be given as a slow infusion over 30 to 60 minutes. Special conditions apply to ensure correct use, including the administration of the first inhalation dose under medical supervision.

Furthermore, population-specific adjustments are mandatory. The dose must be reduced for patients with renal impairment based on Creatinine Clearance (CrCl) guidelines. Systemic dosing for obese patients must be calculated using their Ideal Body Weight. Treatment duration varies significantly, with IV use typically short-term and inhalation often managed on a long-term basis.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Promixin

Evidence for Use in Chronic Lung Infection in Cystic Fibrosis

Research into the inhaled use of Promixin (Colistimethate Sodium) has involved Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were applied in research contexts involving fluctuating or unstable symptoms related to chronic Pseudomonas aeruginosa lung colonization in patients with Cystic Fibrosis (CF), including both children (ge 6 years) and adults. The research primarily examined outcomes related to pulmonary function, specifically measuring changes in Forced Expiratory Volume in one second (FEV1), and monitored the frequency of pulmonary exacerbations.

In these trials, Promixin was evaluated in studies comparing it to other established inhaled antibiotics, rather than a non-treatment (placebo). Findings describe patterns observed in the studies where outcomes related to lung function were observed to be similar between Promixin and the comparator drugs during the study period. However, the long-term effects are not fully established. The follow-up durations were limited, typically lasting between 6 months and 1 year, meaning there is limited information for long-term outcomes regarding the overall slowing of lung function decline.

Evidence for Use as a Last-Resort Antibiotic in Severe Infections

The research landscape for using intravenous Promixin in the management of systemic infections caused by multi-drug-resistant (MDR) Gram-negative bacteria is different. Evidence is mainly derived from settings with varying symptom burdens, including retrospective and prospective cohort studies of critically ill patients in Intensive Care Units (ICU). The studies examined outcomes such as clinical cure, microbiological eradication, and all-cause mortality over short time intervals.

Due to the severity of the illness, Promixin was observed in these studies primarily as part of combination therapy with other antibiotics. Findings indicate that clinical cure rates and mortality patterns were described across the short-term follow-up periods in these highly complex settings. A key limitation is the lack of robust, large-scale RCTs in this area, meaning the evidence quality varies across studies and the certainty remains low compared to chronic disease management. The precise effect of Promixin when used in combination with other antibiotics is difficult to distinguish from the effect of the combined regimen.

Key Studies & References Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model

Frequently Asked Questions (FAQ)

Common questions about Promixin (FAQ)

Q: Does Promixin affect my energy levels or make me feel tired?

A: Official product information indicates that side effects associated with the nervous system may occur. These can include feelings of unusual tiredness or weakness, dizziness, and lethargy. Because of the potential for these effects, official warnings advise caution regarding activities like driving or operating machinery.

Q: What happens if I miss a scheduled time to use Promixin?

A: If you forget a scheduled time, general patient advice, aligned with regulatory standards, is to never take a double dose to compensate. Whether the missed dose should be taken or skipped depends on the time remaining before the next scheduled dose. It is important to follow the specific instructions provided by your healthcare team for managing a missed dose.

Q: Does Promixin have any known interactions with common over-the-counter pain relievers?

A: The official regulatory profile for Promixin cautions against co-administration with other nephrotoxic medicinal products, which are drugs that can potentially harm the kidneys. This general warning exists because of the documented risk of summative kidney damage, and this principle generally indicates why combining medications should be discussed with a healthcare provider.

Q: Is it normal to feel a change in my throat or taste after using Promixin?

A: The most common undesirable effects following nebulisation are a cough and bronchospasm (chest tightness). Furthermore, the drug’s effects on the nervous system can sometimes cause sensations like tingling of the tongue (paresthesia) or dry mouth, which may contribute to a perceived change in the throat or taste.

Q: How does Promixin differ from other treatments for the same condition?

A: Promixin is unique because it is classified as a polypeptide antibiotic belonging to the Polymyxin group. Its primary action is described as detergent-like, working by physically disrupting and destabilizing the outer membrane of susceptible Gram-negative bacteria.

Q: Does using Promixin affect fertility or pregnancy planning?

A: The drug is known to cross the placental barrier. Official guidance indicates that its use during pregnancy is restricted, and a careful assessment of benefit versus risk is necessary. Regulatory summaries do not contain specific information regarding effects on fertility.

Q: Is it common for Promixin to cause a cough or irritation?

A: Yes, according to official documents, cough and bronchospasm (a sudden narrowing of the airways that causes chest tightness) are classified as Very Common undesirable effects following nebulisation. These are the most frequently reported respiratory reactions.

Q: Can people with kidney issues use Promixin?

A: Patients with pre-existing renal impairment face an increased risk of toxicity. Regulatory documents state that use in these patients requires the greatest caution and mandates dosage modification proportional to the degree of kidney function impairment. This adjustment is important because patients with kidney issues face an increased risk of systemic toxicity.

Q: Does using Promixin make me more susceptible to other infections?

A: Regulatory warnings indicate that prolonged use of any antibiotic, including Promixin, may sometimes result in the overgrowth of non-susceptible organisms. Clostridioides difficile-associated diarrhea is also a documented potential risk noted in the official safety profile.

Q: Why do some people need to use Promixin for a long time?

A: The inhalation formulation is officially indicated for the management of chronic pulmonary infections, such as those caused by Pseudomonas aeruginosa in patients with Cystic Fibrosis. The necessity for long-term use is related to the persistent and chronic nature of this specific bacterial infection.

Q: Do I need to store Promixin in the refrigerator?

A: Storage depends on the drug's form. The unreconstituted powder in the original vial should be stored at a temperature not exceeding 25 C (77 F). The reconstituted solution is typically stable for up to 24 hours when stored in a refrigerator (between 2 C and 8 C). Solutions should be used immediately after preparation if possible.

Q: Can children of different ages use Promixin?

A: The drug is approved for use in adults, adolescents, and children. Regulatory cautions advise care for use in infants under 1 year due to potential immaturity of kidney function. In the inhaled formulation, safety and efficacy have been studied in children, often establishing use for those 6 years and older in certain conditions.

Q: Can elderly patients use Promixin safely?

A: Official information indicates that no specific dose adjustments are typically required for older patients who have normal kidney function. However, general caution is advised because this population may have a greater frequency of age-related decreased renal function, which increases the risk of toxicity.

Q: How often are the reported side effects for Promixin?

A: Regulatory documents classify side effects using standardized frequency categories. These include Very Common (affecting more than 1 in 10 people), Common (affecting up to 1 in 10 people), and less frequently reported serious adverse reactions. This classification describes the expected frequency of different types of reactions.

Q: Does Promixin have a cumulative effect over weeks or months?

A: The risk of both kidney (nephrotoxicity) and nervous system (neurotoxicity) damage is explicitly documented as dose-dependent, meaning higher concentrations in the body correlate with greater risk. Safety data also suggests that the potential for cumulative health effects exists with repeated or long-term exposure.

Q: What does 'contraindication' mean in the context of Promixin?

A: A contraindication defines a specific condition or history where the drug must not be used. For Promixin, contraindications include a known history of hypersensitivity or allergy to colistimethate sodium or other polymyxins. Certain official documents also list the nervous system condition Myasthenia Gravis as a contraindication.

Q: Has Promixin been studied in people who also have allergies?

A: The primary regulatory safety focus is on an allergy or hypersensitivity specifically to colistimethate sodium, colistin, or other polymyxins, which is listed as an absolute contraindication. There is limited detailed information in official labeling regarding studies in people with general, non-drug-related allergies.

Q: What does the latest research say about the long-term effectiveness of Promixin?

A: Official research overviews indicate that data is limited regarding long-term outcomes, such as the overall slowing of lung function decline, due to the limited follow-up duration of available clinical trials. The long-term effects of the drug are, therefore, not fully established.

Q: Does Promixin interact with supplements like vitamins or herbal remedies?

A: Regulatory documents confirm the potential for interaction with medicinal products that are substrates for the body’s renal carrier mechanisms (how the body processes drugs through the kidneys). Official patient information encourages informing your healthcare professional about all prescription and over-the-counter medicines, vitamins, minerals, and herbal products.

Q: Can Promixin cause changes in mood or sleep patterns?

A: The drug's documented neurotoxic side effects are those affecting the nervous system. These include confusion, psychosis, mood or mental changes, and dizziness. If these effects occur, they may indirectly affect a patient's overall mental status and sleep.

Q: What happens to Promixin after it has been inhaled—where does it go?

A: Promixin (Colistimethate Sodium, CMS) is a prodrug that transforms inside the body into the active compound, Colistin. When inhaled via nebulisation, the active Colistin is reported to achieve a high local concentration within the pulmonary epithelial lining fluid of the lungs to target local bacteria.

Q: Is Promixin considered a high-risk drug by regulatory bodies?

A: Authoritative bodies like the World Health Organization classify Colistin (the active component) as a critically important antimicrobial. The drug is often reserved for use as a last-resort antibiotic for severe, multidrug-resistant infections due to its specific activity and toxicity profile.

Q: Is it safe to drive or operate machinery while using Promixin?

A: Due to the potential for neurotoxic side effects such as dizziness, confusion, or visual disturbances, if these effects occur, official warnings advise that caution should be exercised regarding activities like driving or operating machinery.

Q: Are there different brand names for the same medicine as Promixin?

A: Yes, Promixin is one brand name for the active substance Colistimethate Sodium. Other regulatory-approved products containing the same medicinal product have also been marketed under names such as Colomycin, Coly-Mycin M, and Colobreathe.

Q: Is Promixin safe for breastfeeding mothers?

A: Regulatory documents confirm that the drug is excreted in breast milk. Due to this excretion, official product information indicates that breastfeeding is generally not advised while receiving therapy with Promixin.

How should Promixin be stored and disposed of?

Storage and Disposal Instructions for Promixin (Colistimethate Sodium)

The storage and disposal of Promixin must adhere strictly to official regulatory conditions to maintain product integrity.

Storage Requirements

Unreconstituted Powder: The vials must be kept in the original package to protect from light and stored at a controlled temperature not exceeding 25 C (77 F). The product must not be frozen and should be stored out of the sight and reach of children.

Reconstituted Solution: If the solution is not used immediately, it is stable for a maximum of 24 hours when kept refrigerated between 2 C and 8 C (36 F and 46 F).

Disposal Requirements

Do not dispose of unused or expired Promixin by pouring it into wastewater or throwing it into household trash. The product must be discarded according to local requirements for unused medicinal products, typically by returning it to a pharmacy or authorized collection point.

Promixin